

The Role of Chromosomal Aberration in Childhood Leukemia

M. Hassanzadeh-Nazarabadi,* A. Modarressi, and H. Miranpour

*Department of Medical Genetics, Faculty of Medicine, Mashhad University of
Medical Science, Mashhad, Islamic Republic of Iran*

Abstract

Leukemia is referred to a group of heterogeneous neoplasia, which results from the hematopoietic cells transformation. Various chromosomal abnormalities have been recognized as primary pathogenetic changes. Clonal chromosomal aberration is found in approximately 80% of childhood acute leukemia. Favourable and poor prognosis karyotypes are evident in such patients. Since cytogenetic play a dominant role in outcome of patients with childhood acute leukemia it is important to associate characteristic cytogenetic with prognostic value in relation to chromosomal abnormalities. Cytogenetic analysis from 51 childhood diagnosed patients under the age of 14 has been performed on the basis of G-banding technique. Each pair of chromosome show unique banding pattern. Various chromosomal abnormalities were evident in this study, these include; numerical disorders such as: monosomy, trisomy, tetrasomy, pentasomy and pseudo-diploidy. Among them monosomies were more prominent than the other aneuploidy. Structural aberrations such as Philadelphia chromosome, gain and loss, inversion and breakage were seen. Each kind of childhood acute leukemia shows different responses to chemotherapy following cytogenetic studies. This finding strongly suggests that, a close association exists between chromosomal abnormalities and the prognostic value and prediction of outcome.

Keywords: Chromosomal abnormalities; Childhood acute leukemia; ALL; AML

Introduction

Leukemia is one of the most common cancers of childhood which is referred to a group of heterogeneous neoplasia which results from hematopoietic cells transformation [8,25]. Leukemic cells propagate initially in bone marrow and lymphatic tissue and then invade peripheral blood and other tissues [8,25].

Studies from various countries have revealed an increasing incidence of childhood leukemia in recent decades. A large set of population-based data from the Nordic society Of Paediatric Haematology and Oncology (NOPHO) revealed an acute leukemia database covering a population of approximately 5 million children aged 0-14 years [17].

Another study indicated that, the annual incidence

* E-mail: nazarabadi@hotmail.com

was 30-40 per million children under 15 years of age [23]. In the age group 1-4 years, a statistically significant annual 2.6% increase in incidence rate of childhood acute lymphocytic leukemia was seen in another study [30].

According to the type of affected cells (myeloid or lymphoid) and the disease process, leukemia divided into four different type, including:

1. Acute lymphocytic leukemia (A.L.L.).
2. Acute myelocytic leukemia (A.M.L.).
3. Chronic lymphocytic leukemia (C.L.L.).
4. Chronic myelocytic leukemia (C.M.L) [8,9,25].

Nearly 75% of childhood leukemia are classified as ALL, 15% as AML whereas CML is relatively rare and only accounts for 2-4% of childhood leukemia [32].

Although the cause of childhood leukemia remains unknown and there is no way to predict or prevent leukemia, environmental and genetic factors play an important role [8,24,25].

Environmental factors are including: Physical agents such as radiations, Chemical agents such as benzene and antineoplastic drugs, viral agents such as Epstein barr virus, HTLV1 and influenza infection [7,11,28,34,42]. Birth weight is one of the few factors that has been associated with childhood leukemia, children weighing 4000gr. or more at birth were at higher risk of ALL than children weighing less [18,29].

Genetics Factors

The risk of leukemia has been increased in some of the heritable and congenital malformations diseases, such as: neurofibromatosis, agammaglobulinemia, bloom syndrome, fanconi and ataxia telangiectasia as well as some chromosomal syndromes like Down and Klinefelter [4,18,25,27,32,37,39]. Further more, monozygotic twin concordance rate is about 25% beyond 5 years of age and the risk to sib in childhood leukemia is 2-4 higher than the population incidence [8,12,25]. This observation again indicates that the genetic factors play an important role in leukemia. One of the strongest pieces of evidence for the genetic basis of cancer at the cellular level is the observation that nearly all cancer are monoclonal in origin, like philadelphia chromosome which is found in the cancer cells of more than 90% of patients with CML [8,40]. Experimental study has shown that mouse fibroblast cells transformed by extracted DNA from the human tumor cell lines, revealed strong tumorigenicity property [5,40]. Such observation strongly suggests that, DNA from human cancer cells have a gene that dominantly shows cancerous properties. Such a gene called oncogene. This gene before being oncogenic, named

proto-oncogene, which play an important role in cell differentiation and growth control [40].

How are proto-oncogenes activated to oncogenes? By mutation, amplification and chromosomal aberration [5].

A large number of publications deal with various oncogenes associated with chromosomal abnormalities [10]. So the primary chromosomal event appeared to determine the biological bases of the disease. Clonal chromosomal abnormalities are found in approximately 80% of children with AML. Favourable prognosis karyotype in patients with AML include: trisomy 21 (Down syndrome) and translocation of 8;21 (q11.2;q13) which show good response to therapy and relatively long survival, in contrast, the AML patients with reciprocal translocation of chromosomes 9;22 (q34;q11) (philadelphia chromosome) show rather poor prognosis. However, among the patients with all kinds of translocations appeared with poor prognosis compare to those with normal karyotype [26,38,41].

Most patients with CML, who have philadelphia chromosome and bcr/abl product, show a good clinical manifestation whereas true philadelphia -negative patients who have no bcr/abl product, appear with worse prognosis [8,25].

Objective

Since cytogenetic characteristics play a dominant role in outcome of patients with childhood acute leukemia, it is important to correlate cytogenetic characteristic and prognostic values to chromosomal abnormalities. In this study chromosomal analysis have been performed on 51 childhood patients under the age of 14.

Materials and Method

Chromosomal cultures from 51 childhood patients were performed, according to the Armes Verma & Arvind Babu [3]. Five drops of whole peripheral blood and bone marrow aspiration sample were placed separately in 5 ml of full addition media (RPMI1640), supplemented with 20% fetal calf serum, penicillin and streptomycin but without phytohemagglutinin. Cultures were incubated in slant position at 37°C for 12 and 24 h. After this period of time 0.2 ml of colcemid was added to each culture tube and then incubated at 37°C for another 2 h. The culture tubes were centrifuged at 800 rpm for 8 min, the supernatant was discarded and 5 ml of 0.075 M potassium chloride was added to each culture tube. Tubes were incubated for additional 15 min at 37°C in water bath. The samples were

centrifuged at 800 rpm for 5 min, the supernatant was discarded and the pellet was resuspended in 5 ml of fresh fixative (3 part ethanol and one part acetic acid).

The tubes were centrifuged at 800 rpm for 5 min, the supernatant was discarded. This step was repeated for 3 times, after the final centrifugation, the pellet was resuspended in 0.5 ml of fresh fixative, 2 to 4 drops was put on wet cold slide by pasteur pipet, then the cells were treated with trypsin solution (10 gr/100cc BSS) at 37°C for 15 sec and stained with Gimsa. The slides were studied under the high magnification phase objective (100×) of photomicroscope for karyotype preparation. Each chromosome was analyzed for its presence and pairing chromosome in well defined order, based on characterised band and number in order of size. The 23 pairs differed in the length of the arms and each showed a unique banding pattern (Plate 1).




Plate 1. Representative of philadelphia chromosome in AML patient.

Table 1. The Range of age and sex of the patients

Total	Male	Female	Age (year)
5	2	3	1-2
20	9	11	3-5
13	3	10	6-8
10	3	7	9-11
3	1	2	12-14

Results and Discussion

Cytogenetic characteristics play a dominant role in childhood acute leukemia and has emerged as one of the most important prognostic factor [35]. In the present study chromosomal study was performed on 51 childhood diagnosed patients under the age of 14 before receiving any therapy.

In Table 1 the patients are classified as sex and age of incidence. The proportion of male and female include, more female (67.7%) than male (35.3%), whereas Cartwright and his colleagues showed equal sex ratio in their study [6]. In another investigation Jackson *et al.* have claimed that, acute leukemia is more common in males at almost every age and this fact remains unexplained [19]. However such a discrepancy results in terms of sex ratio might be indicated that, sex can not be an incidence factor.

The age of onset was more significant at 3-5 years group (Table 1). These results are similar to those of Magnani *et al.*, in north west Italy [30].

In this study patients were grouped into acute lymphocytic leukemia (ALL) and acute myelocytic leukemia (AML). The incidence of ALL (74%) was more prominent than AML (26%). This result is in agreement with the results of the work which carried out by Knox-Macaulay and Brown in the Sultanate of Oman who showed that 66% of their patients diagnosed as ALL, of the remaining (34%) as AML [21].

Cytogenetic Analysis

Four samples appeared with an apparently normal karyotypes (6%), the remaining 47 cases appeared with an abnormal karyotypes (92%). Such frequency of chromosomal abnormalities are comparable with those of Jarsova *et al.* [20] who indicated that, 96% of 79 childhood acute leukemia had abnormal karyotypes. Also the results are in agreement with those reported by Amare and his colleagues [40] in which chromosomal aberration were detected in 95% of 109 cases of acute leukemia.

Various types and frequency of chromosomal aberrations were classified as numerical (aneuploidy) and structural abnormalities in both kind of leukemia (Figs. 1 & 2).

Within each cytogenetic category, aneuploidies are listed in descending order. These include: monosomies of 4,5,6,7,9,10,11,18,21,22 (60%) trisomies of 4,5,6,7,17,18,21 (19.8%), tetrasomies of 12, 19,21 (7.4%) pentasomies of 21,13 (2.8%) pseudodiploidy (10%) (Fig. 1). These results are different with the cytogenetic finding of Susana *et al.*, who showed that,

the frequency of monosomies and trisomies are 1.9% and 3.6% respectively [38]. The reason for Such a discrepancy remains unknown.

Monosomies and trisomies were more evident in ALL, whereas tetrasomy and pseudodiploidy were more frequent in AML (Figs. 3 & 4). Alteration in chromosome number have a strong impact on outcome in childhood leukemia [16].

Structural abnormalities include: Translocation 9.22 (q34;q11) (philadelphia chromosome) (12.8%), addition (8%), deletion (8%), paracentric inversion (4%), breakage (2%) (Fig. 2).

Chromosomal breakage was not evident in AML compare with those of ALL, but on the other hand philadelphia chromosome in AML was prominent in contrast to ALL (Figs. 5 & 6). This result is comparable with the results of others studies, in which the philadelphia chromosome was only present in 3% of

pediatric ALL patients [1,35].

Responses to chemotherapy following cytogenetic studies were different in each type of childhood acute leukemia (AML & ALL). Most of the ALL patients with the philadelphia chromosome-negative (Ph⁻) showed a good remission (Fig. 7), while AML patients with Ph⁺ appeared with poor response and unfavourable prognosis (Fig. 8). These results were comparable with those reported by Arico *et al.* and Riberior *et al.* [1,35] who observed that Ph⁻ in pediatric ALL patients confers a favourable prognosis. In another study Susana *et al.* [38] claimed that, favourable prognosis karyotypes in patients with AML include: constitutional trisomy 21 (Down syndrome) and t (8;21), whereas poor prognosis karyotypes involved Ph⁺. Similar conclusion claimed by Hann *et al.* [15] who explained that, presence of philadelphia chromosome and t (4;11) were unfavourable karyotype and poor prognosis outcome.




Figure 1. Distribution of cytogenetic finding (aneuploidy) in 51 cases of childhood acute leukemia.




Figure 2. Distribution of cytogenetic finding (Structural abnormalities) in 51 cases of childhood acute leukemia.




Figure 3. Distribution of cytogenetic finding (aneuploidy) in childhood acute myelocytic leukemia (AML).




Figure 4. Distribution of cytogenetic finding (aneuploidy) in childhood acute lymphocytic leukemia (ALL).




Figure 5. Distribution of cytogenetic finding (structural abnormalities) in childhood acute myelocytic leukemia (AML).




Figure 6. Distribution of cytogenetic finding (structural abnormalities) in childhood lymphocytic leukemia (ALL).




Figure 7. Representative of treatment outcome in childhood acute lymphocytic leukemia (ALL).




Figure 8. Representative of treatment outcome in childhood acute myelocytic leukemia (AML).

With recurrent treatment protocol only 30-50% of children with AML will have successful outcome [13]. This finding may suggest that hematopoietic stem cell transplantation from a matched sibling donor is the treatment of choice for patient with philadelphia chromosome positive [31]. Therefore it is important to correlate cytogenetic characteristics with disease outcome to identify patients that may benefit from prospective individualized therapy.

Acknowledgement

We wish to express our appreciation to vice president for research of Mashhad University of Medical Science for providing the expense of this project.

Our thanks to Mrs S. Mirzaie, Mrs Z. Rabani and Mrs F. Hasanzadeh for their technical assistance at Medical Genetic Department.

References

1. Arico M., Valsecchi M.G., and Camitta B. Outcome of treatment in children with philadelphia chromosome-positive in acute lymphoblastic leukemia. *N. Engl. J. Med.*, **342**(14): 998-1006 (2000).
2. Amare P., Gladstone B., Varghese C., Pai S., and Advani S. Clinical significance of cytogenetic findings at diagnosis and in remission in childhood and adult lymphoblastic leukemia. *Cancer Genet. Cytogenet.*, **110**(1): 4453 (1999).
3. Arms-Verma and Babu A. *Human Chromosome: Tissue Culture Technique and Chromosome Preparation*. McGraw-Hill, New York, London, pp. 6-71 (1995).
4. Baker J.M., Coppes M.J., and Roland B. A case of down syndrome with acute lymphoblastic leukemia and isochromosome XP. *Cancer Genet. Cytogenet.*, **147**(1): 75-77 (2003).
5. Lewin B. *Gene VII*. Oxford University Press. pp. 875-911 (2001).

6. Cartwright R.A., Gurney K.A., and Moorman A.V. Sex ratios and the risk of haematological malignancy. *Br. J. Haematol.*, **118**(4): 1071-7 (2002).
7. Dockerty J.D., Skegg D.C., Elwood J.M., Herbison G.P., Becroft D.M., and Lewis M.E. Infections, vaccinations and the risk of childhood leukemia. *Br. J. Cancer*, **80**(9): 1483-9 (1999).
8. Braunwald E. and Fauci A.S. *Acute and Chronic Myeloid Leukemia: Principles of Internal Medicine, Harison*, McGraw-Hill, Medical Publishing Division, New York, 15th Ed., 6: pp. 706-714 (2001).
9. Gonzalez J.R., Moreno V., Maria Borrás J., Borrás J., Galceran J., Granena A., and Bosch F.X. Incidence and survival of leukemias according to the different histologic subsets, in Tragona, Spain, between 1980-1994. *Med. Clin. (Barc)*, **116**(5): 174-8 (2001).
10. Gordon W., and Dewald P. 154 chromosome anomalies in hematologic malignancies. *Leukemia Res.*, **24**: 487-489 (2000).
11. Greaves M.F. Childhood leukemia. *BMJ*, **324**: 283-287 (2002).
12. Greaves M.F., Maia A.T., Wiemls J.L., and Ford A.M. Leukemia in twins: lessons in natural history. *Blood*, **102**(7): 2321-33 (2003).
13. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., Rees J., Hann I., Stevens R., Burnett A., and Goldstone A. The importance of diagnostic cytogenetics on outcome in AML. *Blood*, **92**: 2322 (1998).
14. Hemminkik L.I.X. Cancer risk in twins results from the Swedish family. Cancer database. *Int. J. Cancer*, **99**(6): 873-87 (Jun 20, 2002).
15. Hann I., Vora A., and Harrison G. Determination of outcome after intensified therapy of childhood lymphoblastic leukemia. *Br. J. Haematol.*, **113**(1): 103-14 (2001).
16. Harrison C.J. The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukemia. *Blood Rev.*, **15**(1): 49-59 (Mar 2001).
17. Hjalgrim L.L., Rostgaard K., Schmiegelow K., Soderhall S., Kolmann S., Vettenranta K., Kristinsson J., Clausen N., Melbye M., Hjalgrim F., and Gustafsson G. Age and sex-specific incidence of childhood leukemia by immunophenotype in the Nordic Countries. *J. Natl. Cancer Inst.*, **95**(20): 1539-44 (Oct 15, 2003).
18. Hjalgrim L.L., Westergaard T., Rostgaard K., Schmiegelow K., Hjalgrim H., and Engels E.A. Birth weight as a risk factor for childhood leukemia: a metaphase analysis of 18 epidemiologic studies. *Am. J. Epidemiol.*, **158**(8): 724-35 (Oct 15, 2003).
19. Jackson N., Menon B.S., Zarina W., Zawawi N., and Naing N.N. Why is acute leukemia more common in male? A possible sex determined risk linked to the ABO blood group gene. *Ann. Hematol.*, **78**(5): 233-6 (May 1999).
20. Jarosova M., Holzerova M., Mihal V., Lakoma I., Divoky V., Blazek B., Pospisilova D., Hajdich M., Novak Z., Dusek L., Kotikova J., and Indrak K. Complex karyotypes in childhood acute lymphoblastic leukemia, cytogenetic and molecular cytogenetic study of 21 cases. *Cancer Genet. Cytogenet.*, **145**(2): 161-8 (Sep 2003).
21. Knox-Macaulay H.H. and Brown L.C. Descriptive epidemiology of de novo acute leukemia in the Sultanate of Oman. *Leuk Res.*, **24**(7): 589-94 (Jul 2000).
22. Krauter J., Ganser A., Bergman L., Raghavachar A., Hoelzer D., Lubbert M., Schlimok G., Arnold R., Kirchner H., Port M., and Heil G. Association between structural and numerical chromosomal aberration in acute myeloblastic leukemia. *Ann. Hematol.*, **78**: 265-269 (1999).
23. Kusuyama M., Matsumoto K., Mastumoto T., and Tsuji Y. Childhood leukemia: epidemiological investigation and effectiveness in treatment in Nagasaki over the past 12 years. *Acta. Paediatr. JPN.*, **39**(2): 181-7 (Apr 1997).
24. Labuda J. Parental genotype in the risk of complex disease. *Am. J. Human Genet.*, **71**(1): 193-197 (Jul 2002).
25. Lee-Goldman J. and Bennett C. *The Chronic Leukemia*. Text book medicine, Cecil. W.B. Sanders Company, New York, Vol. I, pp. 944-958 (2000).
26. Leverger G., Bernheim A., Daniel M.-T., Flandrin G., Schairson G., and Berger R. Cytogenetic study of 130 childhood acute nonlymphocytic leukemias. *Med. Pediatr. Oncol.*, **40**: 13-22 (1989).
27. Loncarevic I.F., Roitzheim B., Ritterbach J., Viehmann S., Borkhardt S., Lampert F., and Harbott J. Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion. *Gene Chromosomes Cancer*, **24**(3): 272-7 (Mar 1999).
28. Mejia-Arangure J.M. Environmental factors contributing to the development childhood leukemia. *Leukemia*, (9): 19045-1907 (Sep 17, 2003).
29. Murray L., McCarron P., Bailie K., Middleton R., Davey Smith G., Dempsey S., McCarthy A., and Gavin A. Association of early life factors and acute lymphoblastic leukemia in childhood: historical cohort study. *Br. J. Cancer*, **86**(3): 356-61 (Feb 1, 2002).
30. Magnani C., Dalmaso P., Pastor G., Terracini B., Martuzzi M., Moss M.L., and Merletti F. Increasing incidence of childhood leukemia in Northwest Italy. 1975-98. *Int. J. Cancer*, **105**(4): 552-7 (Jul 1, 2003).
31. Mori T., Manabe A., and Tsuchida M. Allogenic bone marrow transplantation in first remission rescues children with Philadelphia chromosome positive acute lymphoblastic leukemia. *Med. Pediatr. Oncol.*, **37**(5): 426-3 (2001).

32. Passarge E. Bloom syndrome: The German experience. *Ann. Genet.*, **34**(3-4): 179-97 (1991).
33. Rosenberg J.R. Cancer incidence in Fanconi anemia. *Blood*, **101**: 822-826 (2003).
34. Ross J.A. Epidemiology of childhood leukemia with focus on infant. *Epidemiol. Review*, **16**(2): 243-72 (1994).
35. Ribeiro R.C., Broniscer A., and Rivera G.K. Philadelphia chromosome positive (ph+) childhood acute lymphoblastic leukemia. *Blood*, **92**(8): 2730-41 (1998).
36. Schoch S. AML with 11q23/MLL abnormality as defined by the WHO classification: incidence, partner chromosomes, age distribution and prognostic impact. *Blood*, **102**(7): 2395-2402 (Oct 1, 2003).
37. Stiller C.A. and Chessells J.M. Neurofibromatosis and childhood leukemia a population-based UKCCSG study. *Br J Cancer*, **70**(5): 969-72 (1994).
38. Raimondi S.C., Chang M.N., Ravindranath Y., Behm F.G., Gresik M.V., Weinstin H.J., and Andrew J. Chromosomal abnormalities in 475 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. *Blood*, **94**: 3707-3716 (1999).
39. Tylor A.M., Metcalfe J.A., and Thick J. Leukemia and lymphoma in ataxia telangiectasia. *Blood*, **87**(2): 4323-38 (1996).
40. Gelehrter T.D. and Collins F.S. *Principles of Medical Genetics*. William and Wilkins: Awaverly Company, London, New York, pp. 245-272 (1988).
41. Woods W.G., Nesbit M.E., Buckley J., Lampkin B.C., Mcc Rennie S., Kim T.H., Piomelli S., and Kersy J.H. For the children's cancer study group: Correlation of chromosome abnormalities with patient characteristic histologic subtype and induction success in children with acute leukemia. *J. Clin. Oncol.*, **3**: 3-8 (1985).
42. Zhang L.D.A. and Estman M.T. The nature of chromosomal aberration detected in human exposed to benzene. *Critical Review in Toxicology*, **32**(1): 1-42 (1999).